HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) — Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin’s rigorous peer-reviewed clinical research validating its proprietary neurostimulation
You May Also Like:
:max_bytes(150000):strip_icc()/GettyImages-1644727881-73ef3c9679a6447faafc74eb0ff22f1e.jpg "6 Fish That Offer the Most Benefits for Your Heart and Brain")